Virbac SA (EPA:VIRP)
France
· Delayed Price · Currency is EUR | Market Cap | 2.52B |
| Revenue (ttm) | 1.40B |
| Net Income (ttm) | 145.29M |
| Shares Out | 8.37M |
| EPS (ttm) | 17.34 |
| PE Ratio | 17.39 |
| Forward PE | 15.50 |
| Dividend | 1.45 (0.48%) |
| Ex-Dividend Date | Jun 25, 2024 |
| Volume | 2,458 |
| Average Volume | 5,636 |
| Open | 304.50 |
| Previous Close | 304.50 |
| Day's Range | 300.50 - 305.50 |
| 52-Week Range | 289.50 - 400.00 |
| Beta | 0.95 |
| RSI | 45.15 |
| Earnings Date | Sep 12, 2025 |
About Virbac
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac... [Read more]
Financial Performance
In 2024, Virbac's revenue was 1.40 billion, an increase of 12.07% compared to the previous year's 1.25 billion. Earnings were 145.29 million, an increase of 19.78%.
Financial StatementsNews
Full Year 2024 Virbac SA Earnings Presentation Transcript
Full Year 2024 Virbac SA Earnings Presentation Transcript
Virbac SA (VRBCF) Q4 2024 Earnings Call Transcript
Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2024
Public release of Virbac Consolidated Accounts at 31 December 2024. The Group released its 2024 Consolidated Accounts.
Virbac: 2024 Annual results
1 variance at constant exchange rates and scope corresponds to the organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the ...
India's Animal Healthcare Industry on a High-Growth Trajectory, Projected to Reach USD 2.0 Billion by 2034| Exclusive Report by Transparency Market Research Inc.
Wilmington, Delaware, Transparency Market Research Inc. – , Feb. 06, 2025 (GLOBE NEWSWIRE) -- The India animal healthcare market is experiencing significant growth, driven by a rising livestock popula...
Virbac: Strong annual revenue growth of +13.6% supported by dynamic organic growth (+7.5%) and the strategic contribution of our acquisitions (+6.1%)
Strong annual revenue growth of +13.6% supported by dynamic organic growth (+7.5%) and the strategic contribution of our acquisitions (+6.1%)
Virbac : Declaration of the number of shares and voti
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the Fre...
The best dog toothpastes that make it easier to brush your pup's teeth
We asked vets about the best dog toothpastes for daily brushing. Our top picks from Petsmile, Virbac, and Arm & Hammer include enzymatic toothpaste.
Virbac: Strong revenue growth as of the end of September at +12.6% and +8.6% at constant exchange rates and scope. 2024 targets maintained.
1 growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indica...
Virbac SA (VRBCF) Q2 2024 Earnings Call Transcript
Virbac SA (OTCPK:VRBCF) Q2 2024 Results Conference Call September 16, 2024 8:00 AM ETCompany ParticipantsSandrine Brunel - Head of Corporate...